MONOCLONAL AB A-33 TO STAGE COLORECTAL CANCER PATIENTS

单克隆 AB A-33 用于对结直肠癌患者进行分期

• 批准号: 2102266
• 负责人: ALFRED M. COHEN
• 金额: $ 16.35万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-08-01 至 1996-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2102266
• 关键词: bone marrow; colorectal neoplasms; gamma radiation; hepatectomy; histopathology; human subject; immunocytochemistry; immunoglobulin G; iodine; liver neoplasms; metastasis; monoclonal antibody; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer relapse /recurrence; radioimmunoassay; radiotracer; scintillation cameras; tumor antigens

The objective of this Interactive R01 (I-R01) submitted in response to the RFA: CA-92-25 is to improve the longterm survival of patients with colorectal cancer metastatic to the liver and to avoid inappropriate treatment programs. This will be accomplished by collaboration amongst the clinical chemotherapy trials (Kemeny I-R01, IRPG Coordinator), studies of drug resistance (Bertino I-R01), and our Studies. The overall goal of this application is to utilize a monoclonal antibody strategy for more accurate Staging by the detection of occult metastatic cancer in patients with clinically isolated hepatic metastases entered into programs under the Kemeny I-R01 clinical trials. We will also obtain operative specimens from this patient population for laboratory study under the Bertino I-R01. Our program will focus on the utilization of the monoclonal antibody A- 33, developed at our institution. The associated antigen is a large molecular weight cell surface glycoprotein that is not secreted into the bloodstream, and the antibody is rapidly internalized after complexing. The patients have clinically isolated hepatic metastases undergoing surgery for hepatic resection or for hepatic artery pump placement for unresectable disease (Kemeny I-R01). Our projects include (1) the detection of occult bone marrow metastases, (2) intraoperative radioimmunodetection with a gamma detecting probe and an innovative intraoperative gamma camera, (3) immunobiological specificity of MAB nodal uptake, and (4) studies with murine IgG and humanized IgG/fragments. The failure to detect occult bone marrow or intra- abdominal extrahepatic metastatic cancer should maximize long-term survival of patients undergoing hepatic resection of hepatic artery chemotherapy. The positive detection of occult extrahepatic disease will avoid inappropriate treatment in such patients.

本互动R01(I-R01)的目标是为回应 RFA：CA-92-25是为了提高患者的长期存活率 结直肠癌转移至肝脏及避免不当转移 治疗方案。这将通过以下方面的合作来实现 临床化疗试验(Kemeny I-R01，IRPG协调员)， 耐药性研究(Bertino I-R01)和我们的研究。整体而言 这个应用程序的目标是利用单抗策略来 通过检测隐匿性转移癌更准确地进行分期 临床孤立的肝转移瘤患者进入 Kemeny I-R01临床试验下的计划。我们还将获得 用于实验室研究的该患者群体的手术标本 在贝尔蒂诺I-R01下。 我们的节目将重点介绍单抗A-的利用。 33，在我们机构开发。相关抗原是一种大的 不分泌到细胞表面的相对分子质量的糖蛋白 血液流动，抗体在络合后迅速内化。 这些患者都有临床上孤立的肝转移瘤。 肝切除或肝动脉置泵手术 不能切除的疾病(Kemeny I-R01)。我们的项目包括(1) 隐匿性骨髓转移的检测，(2)术中 使用伽马探测探头和创新的放射免疫检测 术中伽玛相机；(3)单抗的免疫生物学特异性 结节摄取，以及(4)用小鼠免疫球蛋白和人源化的研究 免疫球蛋白/片段。未能检测到隐匿性骨髓或内部- 腹部肝外转移癌应最大限度地提高长期疗效 肝动脉肝切除术患者的生存分析 化疗。隐匿性肝外疾病阳性检测将 避免对此类患者进行不适当的治疗。